EP0959883A4 - Inhibitoren der farnesyl-protein-transferase - Google Patents

Inhibitoren der farnesyl-protein-transferase

Info

Publication number
EP0959883A4
EP0959883A4 EP97917711A EP97917711A EP0959883A4 EP 0959883 A4 EP0959883 A4 EP 0959883A4 EP 97917711 A EP97917711 A EP 97917711A EP 97917711 A EP97917711 A EP 97917711A EP 0959883 A4 EP0959883 A4 EP 0959883A4
Authority
EP
European Patent Office
Prior art keywords
farnesyl
inhibitors
protein transferase
transferase
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97917711A
Other languages
English (en)
French (fr)
Other versions
EP0959883A1 (de
Inventor
Jeffrey Bergman
Christopher Dinsmore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9610654.7A external-priority patent/GB9610654D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0959883A1 publication Critical patent/EP0959883A1/de
Publication of EP0959883A4 publication Critical patent/EP0959883A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP97917711A 1996-04-03 1997-03-31 Inhibitoren der farnesyl-protein-transferase Withdrawn EP0959883A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1466896P 1996-04-03 1996-04-03
US14668P 1996-04-03
GB9610654 1996-05-21
GBGB9610654.7A GB9610654D0 (en) 1996-05-21 1996-05-21 Inhibitors of farnesyl-protein transferase
PCT/US1997/005170 WO1997036583A1 (en) 1996-04-03 1997-03-31 Inhibitors of farnesyl-protein transferase

Publications (2)

Publication Number Publication Date
EP0959883A1 EP0959883A1 (de) 1999-12-01
EP0959883A4 true EP0959883A4 (de) 2001-05-09

Family

ID=26309375

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97917711A Withdrawn EP0959883A4 (de) 1996-04-03 1997-03-31 Inhibitoren der farnesyl-protein-transferase

Country Status (5)

Country Link
EP (1) EP0959883A4 (de)
JP (1) JP2000507584A (de)
AU (1) AU715604B2 (de)
CA (1) CA2250143A1 (de)
WO (1) WO1997036583A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243507A1 (en) * 1996-01-30 1997-08-07 Christopher J. Dinsmore Inhibitors of farnesyl-protein transferase
JP2000507589A (ja) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
CZ298511B6 (cs) * 1997-12-22 2007-10-24 Schering Corporation Použití benzocykloheptapyridinových sloucenin proprípravu farmaceutického prípravku pro použití v kombinaci s antineoplastickým lécivem a/nebo radioterapií k lécení proliferacních onemocnení
KR100759164B1 (ko) 1998-05-20 2007-09-14 다이니폰 인사츠 가부시키가이샤 단열 용기
WO2000001382A1 (en) 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2002519427A (ja) 1998-07-02 2002-07-02 メルク エンド カムパニー インコーポレーテッド プレニル蛋白トランスフェラーゼ阻害薬
TW200817319A (en) 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3497591A (en) * 1968-11-19 1970-02-24 Colgate Palmolive Co Dental preparations containing imidazole derivative
DE3219113A1 (de) * 1982-05-21 1983-11-24 Bayer Ag, 5090 Leverkusen Verwendung von n-substituierten 2,3-diaminocarbonsaeuren in arzneimitteln und ihre herstellung
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
WO1996030343A1 (en) * 1995-03-29 1996-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996037204A1 (en) * 1995-05-24 1996-11-28 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996039137A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997029092A1 (en) * 1996-02-09 1997-08-14 James Black Foundation Limited Histamine h3 receptor ligands

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2814355C3 (de) * 1978-04-03 1982-01-21 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von 4-Methyl-5-[(2-aminoäthyl)-thiomethyl]-imidazol-dihydrochlorid

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3497591A (en) * 1968-11-19 1970-02-24 Colgate Palmolive Co Dental preparations containing imidazole derivative
DE3219113A1 (de) * 1982-05-21 1983-11-24 Bayer Ag, 5090 Leverkusen Verwendung von n-substituierten 2,3-diaminocarbonsaeuren in arzneimitteln und ihre herstellung
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
WO1996030343A1 (en) * 1995-03-29 1996-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996037204A1 (en) * 1995-05-24 1996-11-28 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996039137A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997029092A1 (en) * 1996-02-09 1997-08-14 James Black Foundation Limited Histamine h3 receptor ligands

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
A. T. UNG, S. G. PYNE: "Synthesis of fluorescent and biotinylated analogues of (1R,2S,3R)-2-acetyl-4(5)-(1,2,3,4-tetrahydroxybutyl)imidazole", TETRAHEDRON LETTERS, vol. 37, no. 34, 1996, pages 6209 - 6212, XP002030837 *
A. WARSHAWSKY ET AL.: "Ring Cleavage of N-Acyl- and N-(Arylsulfonyl)histamines with Di-tert-butyl Dicarbonate. A One-Pot Synthesis of 4-Acylamino- and 4-Arylsulfonylamino-1,2-diaminobutanes", SYNTHESIS, no. 11, 1989, pages 825 - 829, XP002030834 *
ANAL. BIOCHEM., vol. 148, no. 2, 1985, pages 365 - 375 *
ANAL. SCI., vol. 7, no. 6, 1991, pages 959 - 961 *
BIOORG. KHIM., vol. 13, no. 3, 1987, pages 320 - 337 *
BIOORG. KHIM., vol. 16, no. 7, 1990, pages 956 - 962 *
CHEMICAL ABSTRACTS, vol. 103, no. 13, 30 September 1985, Columbus, Ohio, US; abstract no. 101248n, page 293; XP002030842 *
CHEMICAL ABSTRACTS, vol. 106, no. 25, 22 June 1987, Columbus, Ohio, US; abstract no. 210288h, O. S. RESHETOVA ET AL.: "Analysis of N-dansyl peptide methyl esters by means of high performance liquid chromatography and mass spectrometry" page 326; XP002030841 *
CHEMICAL ABSTRACTS, vol. 113, no. 18, 29 October 1990, Columbus, Ohio, US; abstract no. 164723r, A. I. TOCHILIN, I. N. GRACHEVA: "8-Methoxy-5-quinolinesulfonyl chloride, a new fluorogenic reagent for the detection of amines and amino acids" page 864; XP002030840 *
CHEMICAL ABSTRACTS, vol. 116, no. 24, 15 June 1992, Columbus, Ohio, US; abstract no. 247605s, H. NISHIZAWA ET AL.: "Enantioseparation of N-dansyl-DL-amino acids by polyacrylamide gel zone electrophoresis" page 855; XP002030839 *
CHEMICAL ABSTRACTS, vol. 117, no. 16, 19 October 1992, Columbus, Ohio, US; abstract no. 163157e, S. H. LEE ET AL.: "Systematic study on the resolution of derivatized amino acids enantiomers on different cyclodextrin-bonded stationary phases" page 853; XP002030838 *
CHEMICAL ABSTRACTS, vol. 56, no. 5, 5 March 1962, Columbus, Ohio, US; abstract no. 4863e, S. B. SEREBRYANYI ET AL.: "Esters of N(alpha)-arylsulfonyl amino acids" page 1962; XP002030844 *
H. B. MILNE, C.-H. PENG: "The Use of Benzylsulfonyl Chloride in Peptide Syntheses", J. AMER. CHEM. SOC., vol. 79, no. 3, 1957, pages 639 - 644, XP002030836 *
J. CHROMATOGR., vol. 603, no. 1-2, 1992, pages 83 - 93 *
KHIM. ZHUR., vol. 27, 1981, pages 365 - 369 *
L. BAUMANN, T. INGVALDSEN: "Concerning histidine and carnosine. The synthesis of carnosine", J. BIOL. CHEM, vol. 35, 1918, pages 263 - 280, XP002161142 *
M. AMOROSA: "Derivati solfanilamidici dell'istidina", GAZZ. CHIM. ITAL., vol. 71, 1941, pages 343 - 350, XP000984015 *
See also references of WO9736583A1 *

Also Published As

Publication number Publication date
AU2596897A (en) 1997-10-22
JP2000507584A (ja) 2000-06-20
CA2250143A1 (en) 1997-10-09
AU715604B2 (en) 2000-02-03
EP0959883A1 (de) 1999-12-01
WO1997036583A1 (en) 1997-10-09

Similar Documents

Publication Publication Date Title
EP0891350A4 (de) Inhibioten der farnesylprotein-transferase
EP1011669A4 (de) Farnesyl-protein transferase inhibitoren
GB9604311D0 (en) Inhibitors of farnesyl-protein transferase
EP0891360A4 (de) Inhibitoren der farnesyl-protein transferase
EP1045844A4 (de) Inhibitoren von farnesyl-protein-transferase
EP0904080A4 (de) Inhibitoren der farnesyl-protein transferase
EP0880320A4 (de) Inhibitoren der farnesyl-protein transferase
EP0891349A4 (de) Inhibitoren von farnesylprotein-transferase
EP0891352A4 (de) Inhibitoren der farnesyl-protein transferase
EP1035852A4 (de) Hemmer von farnesyl-protein transferase
EP1035850A4 (de) Inhibitoren der farnesyl-protein transferase
EP0891335A4 (de) Inhibitoren von farnesylprotein-transferase
EP0891353A4 (de) Farnesyl-protein transferase inhibitoren
EP0959883A4 (de) Inhibitoren der farnesyl-protein-transferase
EP1035849A4 (de) Farnesyl-protein transferase inhibitoren
EP0877610A4 (de) Inhibitoren der farnesyl-protein transferase
EP1023270A4 (de) Inhibitoren der farnesyl-protein-transferase
EP0900081A4 (de) Inhibitoren der farnesyl-protein transferase
GB9721000D0 (en) Inhibitors of farnesyl-protein transferase
GB9612291D0 (en) Inhibitors of farnesyl-protein transferase
GB9617255D0 (en) Inhibitors of farnesyl-protein transferase
GB9609667D0 (en) Inhibitors of farnesyl-protein transferase
GB9610338D0 (en) Inhibitors of farnesyl-protein transferase
GB9610654D0 (en) Inhibitors of farnesyl-protein transferase
GB9617279D0 (en) Inhibitors of farnesyl-protein transferase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010323

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010608